New schizophrenia drug KarXT shows promise in safety trial
NCT ID NCT06572449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety of a new drug called KarXT in 173 adults with schizophrenia. Researchers slowly increased the dose to see how well participants tolerated it and whether food affected the drug. The main goal was to track side effects, with secondary measures looking at symptom changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KarXT (a combination of xanomeline and trospium)
What this could lead to
If successful, this could provide a new treatment option for schizophrenia with a better understanding of how to manage side effects.
What could go wrong
This is an early-phase study focused on safety, not proof of effectiveness. Side effects like nausea, dizziness, and confusion are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Marlton, New Jersey, 08053-3449, United States
-
Local Institution - 0002
Los Alamitos, California, 90720-3118, United States
-
Local Institution - 0003
Decatur, Georgia, 30030, United States
-
Local Institution - 0004
Riverside, California, 92506-3257, United States
-
Local Institution - 0005
Atlanta, Georgia, 30331, United States
-
Local Institution - 0006
Hollywood, Florida, 33024, United States